British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 11, Issue.: 6
Use of Recombinant Factor VIIa in Obstetrics
Neena Chuni1* and Sachchithanantham Kanagasabai1 1Department of Obstetrics and Gynaecology, Melaka Manipal Medical College, Malaysia.
Neena Chuni1* and Sachchithanantham Kanagasabai1
1Department of Obstetrics and Gynaecology, Melaka Manipal Medical College, Malaysia.
(1) Yoshihiro Nishida , Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Yuhu-City, Japan.
(1) Magdy Abdelrahman Mohamed, Sohag University, Egypt.
(2) D. S. Sheriff, Benghazi University, Benghazi, Libya.
Complete Peer review History: http://sciencedomain.org/review-history/11632
The objective of this review article was to evaluate the current literature on the increasing off-label use of rFVIIa in the management of critical obstetric haemorrhage. Given the lack of high-level evidence, there is a need to review the clinical indications, observed response and adverse events. This review is designed to aid practitioners in deciding when and how to administer rFVIIa; since the current evidence from observational studies shows that benefits outweigh risks in its use as an adjunct to conventional treatment in massive haemorrhage. However, pregnancy is a potentially thrombogenic state, hence a cautious approach is required in patients with risk factors for thromboembolic complications.
rFVII; obstetric haemorrhage; postpartum acquired haemophilia; Jehovah’s witnesses.
Full Article - PDF Page 1-14
DOI : 10.9734/BJMMR/2016/20737Review History Comments